ChiCTR2400083271 版本V1.0 版本创建时间2024/04/19 14:28:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400083271 

最近更新日期:

Date of Last Refreshed on:

2024-04-19 14:27:49 

注册时间:

Date of Registration:

2024-04-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

中药随机对照试验偏倚风险评估体系(cRoB)评价研究

Public title:

Evaluation of risk of bias tool for randomized controlled trials of traditional Chinese medicine (cRoB)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中药随机对照试验偏倚风险评估体系(cRoB)评价研究

Scientific title:

Evaluation of risk of bias tool for randomized controlled trials of traditional Chinese medicine (cRoB)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

向玲慧 

研究负责人:

向玲慧 

Applicant:

Xiang Linghui 

Study leader:

Xiang Linghui 

申请注册联系人电话:

Applicant telephone:

+86 185 7014 4366

研究负责人电话:

Study leader's
telephone:

+86 185 7014 4366

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Xiang.Linghui@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

Xiang.Linghui@outlook.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市湘雅路110号

研究负责人通讯地址:

湖南省长沙市湘雅路110号

Applicant address:

110 XiangYa Road, Changsha, Hunan, China

Study leader's address:

110 XiangYa Road, Changsha, Hunan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学湘雅公共卫生学院

Applicant's institution:

Xiangya School of Public Health, Central South University

研究负责人所在单位:

中南大学湘雅公共卫生学院

Affiliation of the Leader:

Xiangya School of Public Health, Central South University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XYGW-2024-47号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中南大学湘雅公共卫生学院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Xiangya School of Public Health, Central South University, China

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-28 00:00:00

伦理委员会联系人:

关岚

Contact Name of the ethic committee:

Guan Lan

伦理委员会联系地址:

湖南省长沙市湘雅路110号

Contact Address of the ethic committee:

110 XiangYa Road, Changsha, Hunan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 133 9745 3611

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中南大学湘雅公共卫生学院

Primary sponsor:

Xiangya School of Public Health, Central South University

研究实施负责(组长)单位地址:

湖南省长沙市湘雅路110号

Primary sponsor's address:

110 XiangYa Road, Changsha, Hunan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国大陆

省(直辖市):

湖南

市(区县):

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅公共卫生学院

具体地址:

湖南省长沙市湘雅路110号

Institution
hospital:

Medical Ethics Committee, Xiangya School of Public Health, Central South University, China

Address:

110 XiangYa Road, Changsha, Hunan, China

经费或物资来源:

国家自然科学基金面上项目(No. 81973709)

Source(s) of funding:

National Natural Science Foundation of China (No. 81973709)

研究疾病:

偏倚风险评估工具  

Target disease:

Risk of bias tool

研究疾病代码:

Target disease code:

研究类型:

流行病学研究

Study type:

Epidemilogical research

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

开展随机对照试验研究,以评价和比较cRoB与考克兰偏倚风险评估工具2(RoB2)的信度以及偏倚风险评估结果差异  

Objectives of Study:

Conduct a randomized controlled trial study to evaluate and compare the reliability of cRoB versus RoB2 and differences in risk of bias assessment results

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)湖南省长沙市内医学院特定专业(包含临床医学、护理学、公共卫生与预防医学、中医学、中西医结合和中药学)的在读博士、硕士研究生(2)没有以(共同)第一作者/通讯作者身份发表过有关RCT的meta分析(3)未接受过偏倚风险评价训练(4)同意参加本研究者。

Inclusion criteria

(1) Doctoral and master's degree students enrolled in specific specialties (including clinical medicine, public health and preventive medicine, traditional Chinese medicine, integrated Chinese and Western medicine, and traditional Chinese medicine) in medical schools within Changsha, Hunan Province (2) have not published meta-analyses of RCTs as (co-)first/corresponding authors (3) have not received training in the evaluation of the risk of bias (4) who agreed to participate in this study.

排除标准:

1.拒绝参与研究

Exclusion criteria:

1. Refuse to participate in the research

研究实施时间:

Study execute time:

From 2024-04-20 00:00:00 To 2024-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-04-20 00:00:00 To 2024-04-22 00:00:00

干预措施:

Interventions:

组别:

cRoB

样本量:

12

Group:

cRoB

Sample size:

干预措施:

cRoB

干预措施代码:

Intervention:

cRoB

Intervention code:

组别:

RoB2

样本量:

12

Group:

RoB2

Sample size:

干预措施:

RoB2

干预措施代码:

Intervention:

RoB2

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国大陆

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅公共卫生学院 

单位级别:

无 

Institution
hospital:

Xiangya School of Public Health, Central South University

Level of the institution:

N/A

测量指标:

Outcomes:

指标中文名:

各维度共识前评价者间一致性

指标类型:

主要指标

Outcome:

Pre-consensus inter-rater reliability of each dimension

Type:

Primary indicator

测量时间点:

各组12名研究对象独立完成评价后,两两配对达成共识之前

测量方法:

计算各组12名研究生各个维度的偏倚风险的Fleiss’ Kappa值

Measure time point of outcome:

After each group of 12 research subjects completed the evaluation independently, before the pair reached a consensus

Measure method:

Calculation of Fleiss' Kappa values for risk of bias for each dimension for each group of 12 graduate students

指标中文名:

各维度共识后评价者间一致性

指标类型:

主要指标

Outcome:

Post-consensus inter-rater reliability of each dimension

Type:

Primary indicator

测量时间点:

各组两两配对达成共识之后

测量方法:

计算各组6对研究生各个维度的偏倚风险的Fleiss’ Kappa值

Measure time point of outcome:

After the groups are paired up in pairs to reach a consensus

Measure method:

Calculate the Fleiss’ Kappa value of the risk of bias in each dimension for each group of 6 pairs of graduate students.

指标中文名:

总偏倚风险共识前评价者间一致性

指标类型:

次要指标

Outcome:

Pre-consensus inter-rater reliability of total risk of bias

Type:

Secondary indicator

测量时间点:

各组12名研究对象独立完成评价后,两两配对达成共识之前

测量方法:

计算各组12名研究生总偏倚风险的Fleiss’ Kappa值

Measure time point of outcome:

After each group of 12 research subjects completed the evaluation independently, before the pair reached a consensus

Measure method:

Calculation of Fleiss' Kappa values for total risk of bias for 12 graduate students in each group

指标中文名:

总偏倚风险共识后评价者间一致性

指标类型:

次要指标

Outcome:

Post-consensus inter-rater reliability of total risk of bias

Type:

Secondary indicator

测量时间点:

各组两两配对达成共识之后

测量方法:

计算各组6对研究生总偏倚风险的Fleiss’ Kappa值

Measure time point of outcome:

After the groups are paired up in pairs to reach a consensus

Measure method:

Calculation of Fleiss' Kappa values for total risk of bias for 6 pairs of graduate students in each group

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 30 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与后续研究的统计学专家进行最小化随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Minimized randomization by statisticians not involved in the follow-up study

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

仅对数据分析者实施盲法

Blinding:

Blind method only for data analysts

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

N/A

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

N/A

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

N/A

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-04-19 14:27:49